Evidence map›Paper›PMID 38509572›Full record

ArticleMicrobial cell factories2024

Modifications of the 5' region of the CASPON

Christoph Köppl, Wolfgang Buchinger, Gerald Striedner, Monika Cserjan-Puschmann

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Christoph KöpplAustrian Centre of Industrial Biotechnology, Muthgasse 18, Vienna, 1190, Austria.
Wolfgang BuchingerBiopharma Austria, Development Operations, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, Dr.-Boehringer-Gasse 5-11, Vienna, A-1121, Austria.
Gerald StriednerAustrian Centre of Industrial Biotechnology, Muthgasse 18, Vienna, 1190, Austria.
Monika Cserjan-PuschmannAustrian Centre of Industrial Biotechnology, Muthgasse 18, Vienna, 1190, Austria. monika.cserjan@boku.ac.at.
BOKU University · ATAustrian Centre of Industrial Biotechnology (Austria) · ATBoehringer Ingelheim (Austria) · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEscherichia coli is one of the most commonly used host organisms for the production of biopharmaceuticals, as it allows for cost-efficient and fast recombinant protein expression. However, challenging proteins are often produced with low titres or as inclusion bodies, and the manufacturing process needs to be developed individually for each protein. Recently, we developed the CASPON

resultsIn the present work, we found that by modifying the 5'UTR sequence of a pET30acer plasmid-based system, expression of the fusion protein CASPON

conclusionsThis study reveals some of the complex interdependencies between the ribosome and mRNA that govern recombinant protein expression. By modifying the 5'UTR to obtain an optimized interaction energy between the mRNA and the ribosome (ΔG

Indexed as

CarbonEscherichia coli5' Untranslated RegionsCodonRecombinant Fusion ProteinsRecombinant ProteinsRNA, Messenger5' Untranslated RegionsCarbonCodonRecombinant Fusion ProteinsRecombinant ProteinsRNA, Messenger5’UTRCASPONTM technologyFree folding energyFusion tagRare codonsRecombinant protein

Identifiers

PMID38509572
PMCPMC10953258
OpenAlexW4393010228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.